Isomorphic Labs previewed the Isomorphic Labs Drug Design Engine (IsoDDE), positioning it as an upgrade path beyond AlphaFold-driven structure prediction. The company claims IsoDDE more than doubles AlphaFold 3 accuracy on a protein–ligand prediction benchmark, can predict binding affinities with reported accuracy surpassing physics-based methods, and identifies novel binding pockets from amino-acid sequence input. IsoDDE is presented as a unified computational engine intended to bridge structure prediction and downstream drug-discovery tasks, including affinity prediction and pocket discovery. The report ties its development to the pace after AlphaFold 3’s 2024 release with Google DeepMind. The announcement is focused on performance claims and technical capability demonstrations; it does not describe an associated regulatory submission or specific clinical pipeline molecule.